¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º h7eb/xEto  
2?qT,pN  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ 0=+feB1T  
V1,p<>9  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) SOPair <r  
zSA"f_e  
1. ICAM-1 #+<YFm\i  
zZd. U\"2  
2. interleukin 12(IL-12) bRggt6$z  
d v4~CW%Td  
3. tumor infiltrating lymphocyte E 6#/@C,  
BJ_"FG  
4. TCR/CD3 complex C6gp}%  
i\ uj>;B  
5. hematopoietin receptor family K:13t |  
k^d^Todq.  
6. individual idiotype(IdI) O:'qwJ# ~  
J>M9t%f@  
7. integrin leF!Uog  
du0o4~-  
8. colony-stimulatory factor (CSF) w3VgGc~  
d %FLk=]  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© rosD)]I7  
2xUgM}e  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? ?c8( <_I+  
Xhyn! &H5  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ Jza ?DhSAZ  
TC2%n\ GH*  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠp,f$9t4  
ukVBC"Ny  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ `<P:l y.  
Cb|1Jtb  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 3mopTzs)  
Y~!A"$   
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ $!$If( 7  
} 7:T? `V:  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) }/\`'LQ  
h-O;5.m-P  
3. immunoglobulin superfamily (IgSF) 9 !UNO  
q$b 4S4Z7  
4. selectin 3b#L*-  
? F!c"+C  
5. anti-idiotypic antibody (¦ÁId) q7_Ttjn-DV  
/:{4,aX2  
6. major histocompatibility complex(MHC) <}'=@a  
SO STtuT  
7. immunotolerance bWlY Q  
=-r); d   
8. biological reponse modifier(BRM) f9},d1k  
NOkgG0Z  
9. immune reponse gene (Ir gene) %,<Ki]F  
h 6?Z  
10. reshaped antibody (or reconstituted antibody) M=&,+#z<V  
6r D]6#D  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© }(XKy!G6  
3iX\):4  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ uM,Ps}  
-r3 s{HO  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? P7Qel,  
Y.tT#J^=  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£  QX<x2U  
bX:h"6{=R  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? Ar,n=obG  
}P{Wk7#Jq  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ O1t$]k:  
-TG ="U  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? ~7*2 Jp'  
hLk6Hqr7  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ,5ZQPICF  
0jjtx'F  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ :E~rve'  
b l+g7g;  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? 7[u>#8  
p)?6#~9$  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ y5+%8#3  
7C3YVm6g  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: 2ag8?#  
P#XV_2  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: S 593wfc  
Iapz,nuE  
ÃâÒßѧ  <9yh:1"X  
p@4GI[4  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 51#OlvD  
A( vdlj  
1. CD8 )hj:Xpj9#  
je2_ .^  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 1nskf*Z  
*pS 7,Hm  
3. immunoglobulin fold(Ig fold)  G7a l@  
l&qCgw  
4. cadherin (Ca-dependent cell adhesion moleculers) N~mr@rXC  
z"UC$  
5. idiotype-anti-idiotypic antibody immune network theory /+SLq`'u)  
B<m0YD?>~>  
6. HLA class II antigen S\&3t}_  
ty0P9.Q  
7. complementarity-determining region (CDR) U"p</ Q  
<c pc k  
8. perforin(or pore-forming protein ,PFP) PKSfu++Z  
4Qf sxg  
9. high affinity IL-2 receptor l_+@Xpl  
gK[;"R)4o@  
10. artificial active immunization mSxn7LG  
TD}<U8I8_  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© _q27 3QG/"  
hb5K"9Y  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ1I9v`eT4  
S v>6:y9?G  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 -o6rY9\_!  
!-f Bw  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ @ivd|*?k0  
d7X&3L%Oq  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ `R[ZY!=+  
[s { !  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ (G>[A}-  
eyJ07  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? 5:h[%3'bB  
WKEb '^  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ]yU"J:/  
%X{Eupi FA  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ d,"LZ>hNY*  
`Z?wj@H1`  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Ic#xz;elM  
DZ8|20b  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ kz"uTJK  
'x!\pE-  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© x%G3L\ 5  
??rS h Mu  
1. immunoglobulin gene rearrangement ?['!0PF  
&_ekA44E  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) a:h<M^n049  
I{`70  
3. flow cytometry(FCM) S\ k<  
X W)TI  
4. carrier effect Bh>L"'.2  
dj0; tQ=C  
5. positive selection of T lymphocytes in thymus 7F^d-  
~C.*Vc?|  
6. mouse TH1(Th1) and TH2(Th2) subsets \N> -+r  
'X`Z1L/  
7. perforin (pore-forming protein ,PFP) Lsmcj{1d  
)*,/L <  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) aER|5!7(2\  
<qCa 9@Ea  
9. SH-2(src-homology region 2) DX>a0-Xj  
H"P b)t  
10. Ab2¦Â (internal image) h~MV=7 lE  
=8kmFXo  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© )s2] -n}W  
W L$^B@gXQ  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? L"L3n,%F  
YdY-Jg Xm  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? E-MPFL  
+Q*`kg'  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠTBh M^\z  
e _vsiT  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ bQll;U^A  
]6&NIz`:,  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠZS Med(//b  
MfTLa)Rz  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) Otn,UoeeB  
R+sT &d  
ÃâÒßѧרҵ£º 4 p_C+4  
y>{: [L9*  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ \?:L>-&h8  
*P()&}JK  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? ?5|;3N/zt  
Urj*V0^  
´«È¾²¡Ñ§×¨Òµ£º 2`yhxO  
NGra/s,9 |  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ h@)U,&  
xQ?>72grP  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ D+8d^-:  
[^>XR BSm  
Ïû»¯×¨Òµ£º Hg+<GML  
Nk~}aj  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ LvG.ocCG  
Z['.RF'`  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ?  ^ 5 >e  
4Z)4WGp!  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ w+o5iPLX  
Tw~R-SiS`s  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© >T$0*7wF  
Z[vx0[av&  
1. Fas(CD95)/FasL #ydold{F  
[hJ1]RW8  
2. common chain of cytokine receptor /iW+<@Mas  
,CE/o7.FG  
3 . TCR/CD3 complex l,ny=Q$[1'  
AbU`wr/h 4  
4. negaive selection of thymocytes %V_ XY+o  
D{9a'0J  
5. artificial active immune uH_KOiF  
z%&FLdXgW+  
6. anti-idiotypic AR"2?2<mJ7  
w,~*ead  
7. IgSF D#jwI,n}x  
b[%@3}E  
8. Integrin e8,_"_1 :F  
uJ`N'`Z  
9. chemokine /4{WT?j  
EPo)7<|>  
10. B7/CD28 7uB x  
g&RpE41x  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© o)Q4+njT@  
P0N/bp2Uy  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ Z;+,hR((  
2[ sY?C  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ z/Lb1ND8  
V[ UOlJ  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ as07~Xvp-  
%<i sdvF  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ vuQA-w7  
$G=^cNB|JB  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ /Pjd"  
^Ks1[xc*`  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ 4vg,g(qi<  
dJ"44Wu+J  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© DVQr7tQf  
?[Yn<|  
1. B7/CD28 o HK   
fb f &bJT  
2. Th1 subset 8%4;'[UV  
S iNgV\('U  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© h]zok}$  
lh-.I]>&`  
4. antibody affinity maturation q\tr&@4iC  
a- *sm~u  
5. AP-1 NbWEP\dS'z  
 hyxv+m[  
6. single chain variable fragment£¨ScFv£© Jq1oQu|rs  
#m#IBRD:  
7. NK cell receptor G-CL \G\n  
,]wab6sY  
8. Zinkernagel-Doherty phenomenon hn.(pI1  
<B%wq>4S  
9. Ig fold 03?ADjO  
ImQ -kz?b  
10. CD40/CD40L 5REH`-  
5nc W s)  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© Gn7\4,C  
*b;)7lj0h  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ hl[<o<`Q  
 -raK  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ]:ca=&>  
Sh;`<Ggi~  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ :qS~"@?<  
g=KK PSK  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ l=" (Hp%b  
2 SU'lh\E  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 2U%t  
!B[ Y?b:  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ B l)D/  
)1 @v<I  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ r:xg#&"*  
Jv(E '"H  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ~+6#4<M.~  
jKP75jm  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© :wzbD,/M  
6 y"r '  
1.Co-stimulators (or co-stimulating molecules) 5m;pHgkb  
>yyu:dk-;  
2.NK-kB sS)tSt{C  
q q^[(n  
3.Immunoglobulin superfamily F0m[ls$  
?h7[^sxJ  
4.antigen-presenting cell (APC) Ty 6XU!  
"{{@N4^  
5.death domain Ux,dj8=o  
PHsM)V+  
6.CCR and CXCR DL_M#c`<  
X7aj/:fXe  
7.Lectin (or mitogen) */]1?M@P)  
4[0.M  
8.Clusters of differentiation, CD) ?s0")R&  
)P/~{Ci:T&  
9.B7 family [o'}R`5)  
v|kL7t)}  
10.Cytotoxic T lymphocyte, CTL)  wZ8LY;  
%D^j7`Z  
11.IL-15 and IL-15 receptor (IL-15R) (+\K  
piUfvw  
12.MHC restriction avv/mEf-f  
TwE&5F*  
13.Affinity-chromatography [h :FJ  
1n ZE9;o  
14.Cyctosprin A, CsA _`94CC:  
 hWu#}iN  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) p4zV<qZ>e  
"_&HM4%!  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© -aMwC5iR@  
M#>f:_`<  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 dv \ oVD  
(aH_K07  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ q} R"  
DU4Prjb'  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ 4~r=[|(aY  
hMs}r,*  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 7" cgj#  
Ts:pk  
ÃâÒßѧרҵ£º 2\!.w^7'^T  
PFIL)D |G  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ p>p=nLK  
ffyKAZ{]po  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ W,>;`>  
MhB kr{8  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ Lp/]iZ@  
A]vQ1*pnk  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) Z,,Wo % )o  
[XQoag;!  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) c>3W1"  
GRj{*zs  
1. ADCC(antibody dependent cell-mediated cytotoxicity) S*CRVs  
^f1}:g  
2. »·æß¾úËØ(cyclosporin) @,sg^KB  
p<6pmW3  
3. KIR(killer cell inhibitory receptor) TaB35glLY  
.x1EdfHed/  
4. HLDA(human leucocyte differentiation antigen) (F7!&]8%  
n4CzReG  
5. Interleukin 18(IL-18) !=0N38wA  
Xf9VW}`*8  
6. ÕûºÏËØ(integrin) $X-,6*  
;LH?Qu;e  
7. Fas/FasL 8F4#E U  
12E@9s$Z  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) %-T]!3"n  
E( *$wD  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) r0j:ll d  
K| Y r  
10. Th1/Th2 v?h#Ym3e<  
M6|Q~8$  
11. »ùÒòÒßÃç(DNAÒßÃç) K#F~$k|1B  
G*wn[o(^j  
12. chemokines and chemokine receptor **0Y*Ax@  
kRE^G*?  
13. ÃâÒßÄÍÊÜ 9[6*FAFJPP  
<h7C_^L10\  
14. ¹²´Ì¼¤·Ö×Ó HcQ{ok9u  
eVbHPu4  
15. ËÀÍö½á¹¹Óò(death domain) +69sG9BA  
<r 3F*S=  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)  O,xU+j~)  
i':<Ro  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? KH2a 2  
<t gJ-rnL  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠm]Z& .,bA  
P",~8Aci(  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î zj`!ZY?fv  
jcOxtDTSW  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ A'6>"=ziP  
i>q]U:U  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå qV^,muyoG  
Gv6EJV1i  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ 3MiNJi#=2  
+vBq,'k`  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) .v0.wG  
AXz'=T}{  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ I6'U[ )%  
;&^S-+  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ x(5>f9bb  
:kfl q  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»